Atlas Trials

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

Clinical trial NCT05107128 · COMPLETED

Trial details

NCT number
NCT05107128
Sponsor
Supernus Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Huntington's Disease
Start date
2022-01-26
Primary completion
2024-09-04
Enrollment
189

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.